The Hygiology Post ® is presenting information about a company that seems to have much potential to help many people. The years 2012, 2013, and 2014 do appear to likely be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site. As a matter of disclosure : The author continues to be a current shareholder in the company.
An article dated 6/25/2014 and titled “Senesco Presents Company Update at 2014 BIO International Convention” (https://www.senesco.com/newsitem.php?id=305; retrieved on 6/26/2014) was placed on the web site yesterday. Here is an excerpt:
“Clinical Development Update
The clinical evaluation of SNS01-T has proceeded well. Top-line results are delayed due to slow patient enrollment despite the recent addition of two sites in the Republic of South Africa. In cohort 4 (0.375 mg/kg dose level) three of the required six patients are evaluable and three additional evaluable patients are needed to complete the Phase 1b/2a study. The study is expected to be completed in the second half of 2014.
The overall goal of the newly combined company is to become a preeminent player in advanced biologics drugs and technologies, including antibody and nanoparticle therapeutics. A detailed development strategy will be announced in early Q3 2014. The Company plans to seek a listing on a major exchange as soon as it meets and can maintain listing requirements.”
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2014 The Hygiology Post ®